Harm Minimisation Drug Policy Implementation Qualities: Their Efficacy with Australian Needle and Syringe Program Providers and People Who Inject Drugs.

Danielle Resiak, Elias Mpofu, Roderick Rothwell
Author Information
  1. Danielle Resiak: Faculty of Medicine and Health, School of Health Sciences, The University of Sydney, Sydney, NSW 2006, Australia. ORCID
  2. Elias Mpofu: Faculty of Medicine and Health, School of Health Sciences, The University of Sydney, Sydney, NSW 2006, Australia. ORCID
  3. Roderick Rothwell: Faculty of Medicine and Health, School of Health Sciences, The University of Sydney, Sydney, NSW 2006, Australia.

Abstract

(1) Background: Policies and laws in several jurisdictions across the globe have aimed to promote harm minimisation or reduction, through the implementation of Needle and Syringe Programs (NSP) for People who inject drugs (PWID), for whom abstinence may not be possible or desired. While NSPs hold great promise, their implementation qualities are understudied. (2) Aim: We aimed to examine the implementation quality priorities of NSP providers and PWID consumers in an Australian setting. (3) Method: This study utilised a Quantitative-qualitative (QUAN-qual) mixed methods approach. Survey participants included both PWID ( = 70) and NSP providers ( = 26) in Australia. (4) Results: Results following non-parametric data analysis indicate NSP providers prioritised NSP implementation qualities in the following order: compatibility, observability, relative advantage, resourcing and trialability. Contrary to which, PWID prioritised resourcing, compatibility, relative advantage and trialability, respectively. Findings demonstrate that efficacy of implementation qualities is dependent on the juxtaposition of service provision and utilisation whereby implementation quality priorities are balanced. (5) Conclusions: This research presents novel findings guiding NSP harm reduction programmes for sustainability framed on provider and consumer implementation quality priorities. We envisage future studies on boundary conditions of NSP harm reduction implementation in other jurisdictions.

Keywords

References

  1. Drug Alcohol Rev. 2013 May;32(3):312-9 [PMID: 23194468]
  2. BMC Public Health. 2017 Sep 29;17(1):757 [PMID: 28962604]
  3. Implement Sci. 2014 Aug 20;9:108 [PMID: 25138688]
  4. Drug Alcohol Rev. 2008 Jul;27(4):357-60 [PMID: 18584384]
  5. Med J Aust. 2005 Feb 7;182(3):140; author reply 141 [PMID: 15698366]
  6. Int J Drug Policy. 2017 Nov;49:117-125 [PMID: 28886887]
  7. Int J Drug Policy. 2016 Jan;27:138-45 [PMID: 26394538]
  8. Healthcare (Basel). 2021 Oct 21;9(11): [PMID: 34828463]
  9. BMJ. 2013 Nov 20;347:f6753 [PMID: 24259324]
  10. Drug Alcohol Rev. 2006 Sep;25(5):439-44 [PMID: 16939939]
  11. Int J Drug Policy. 2021 Oct;96:103387 [PMID: 34330571]
  12. Int J Drug Policy. 2018 Apr;54:18-25 [PMID: 29367011]
  13. AIDS Educ Prev. 2005 Feb;17(1):68-78 [PMID: 15843111]
  14. Drug Alcohol Rev. 2018 Jul;37(5):653-657 [PMID: 29851167]
  15. BMC Health Serv Res. 2016 Jul 07;16:224 [PMID: 27388224]
  16. Drug Alcohol Depend. 2013 Dec 1;133(2):600-6 [PMID: 24008022]
  17. Int J Drug Policy. 2015 Jul;26(7):688-95 [PMID: 25979789]
  18. Int J Drug Policy. 2011 Jan;22(1):34-40 [PMID: 20413288]
  19. Harm Reduct J. 2018 Apr 10;15(1):12 [PMID: 29631613]
  20. Drug Alcohol Depend. 2020 Nov 1;216:108267 [PMID: 32916518]
  21. AIDS Educ Prev. 2014 Jun;26(3):234-44 [PMID: 24846486]
  22. Drug Alcohol Rev. 2008 Jan;27(1):13-9 [PMID: 18034377]
  23. Paediatr Child Health. 2008 Jan;13(1):53-60 [PMID: 19119355]
  24. Bull World Health Organ. 2004 Oct;82(10):724-31; discussion 732 [PMID: 15643791]
  25. Drug Alcohol Depend. 2020 Apr 1;209:107899 [PMID: 32086179]
  26. Int J Drug Policy. 2016 Aug;34:65-71 [PMID: 27449331]
  27. Bull World Health Organ. 2019 Sep 1;97(9):605-611 [PMID: 31474773]
  28. BMJ. 2015 Apr 17;350:h2053 [PMID: 25888112]
  29. Int J Drug Policy. 2014 Sep;25(5):865-70 [PMID: 24559604]
  30. Lancet Glob Health. 2017 Dec;5(12):e1208-e1220 [PMID: 29074410]
  31. Addict Behav. 2008 Dec;33(12):1602-5 [PMID: 18762384]
  32. Drug Alcohol Rev. 2020 May;39(4):365-374 [PMID: 32101629]
  33. Milbank Q. 2004;82(4):581-629 [PMID: 15595944]
  34. Int J Drug Policy. 2018 Nov;61:31-37 [PMID: 30388567]
  35. Int J Drug Policy. 2015 Feb;26 Suppl 1:S5-11 [PMID: 25727260]
  36. PLoS One. 2016 Sep 09;11(9):e0162399 [PMID: 27611849]
  37. Subst Use Misuse. 2020;55(6):900-908 [PMID: 31918611]
  38. Drug Alcohol Rev. 2010 Jul;29(4):349-51 [PMID: 20636648]
  39. Adv Prev Med. 2012;2012:269123 [PMID: 23198158]
  40. Addict Behav. 2018 Jan;76:305-311 [PMID: 28889059]
  41. Drug Alcohol Depend. 2018 Oct 1;191:259-265 [PMID: 30153607]

Word Cloud

Created with Highcharts 10.0.0implementationNSPPWIDqualitiesharmreductionqualityprioritiesproviderscompatibilityrelativeadvantageresourcingtrialabilityjurisdictionsaimedNeedleSyringeAustralian=followingprioritisedobservabilityserviceprovider1Background:PolicieslawsseveralacrossglobepromoteminimisationProgramspeopleinjectdrugsabstinencemaypossibledesiredNSPsholdgreatpromiseunderstudied2Aim:examineconsumerssetting3Method:studyutilisedQuantitative-qualitativeQUAN-qualmixedmethodsapproachSurveyparticipantsincluded7026Australia4Results:Resultsnon-parametricdataanalysisindicateorder:ContraryrespectivelyFindingsdemonstrateefficacydependentjuxtapositionprovisionutilisationwherebybalanced5Conclusions:researchpresentsnovelfindingsguidingprogrammessustainabilityframedconsumerenvisagefuturestudiesboundaryconditionsHarmMinimisationDrugPolicyImplementationQualities:EfficacyProgramProvidersPeopleInjectDrugs

Similar Articles

Cited By

No available data.